About us

The EBOVAC2 Consortium brings together Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) as Project Leader and Inserm as Coordinator with its leading expertise in the coordination of large clinical trials in Europe and Africa (ISO 9001:2008 certification), coordination of vaccine and immune intervention trials (especially in HIV) and Immune monitoring in HIV infections and other diseases as well as Inserm’s key infrastructures notably EUCLID (Trials Services Platform & Development) and the Jean Mérieux BSL4 Laboratory possessing the highest level of international biological safety standards to ensure that the EBOVAC vaccine regimen can demonstrate efficacy in non-human primates.

lab1© Janssen

The London School of Hygiene & Tropical Medicine has played key roles in many vaccine trials conducted in developing countries ranging from phase 1 to phase 2b large scale safety and immunogenicity study. LSHTM is well qualified to support many aspects of multidisciplinary trials of Ebola vaccines. The University of Oxford group has been running vaccine clinical trials with children and adults in the UK and will bring its expertise to EBOVAC2 for Phase 2 studies.       

EBOVAC2’s African partner - the CENTRE MURAZ- will ensure strong African involvement in the clinical trials and associated activities notably communication and capacity building. Inserm Transfert, with its dedicated and professional European Project Management and IPR management teams, will ensure that EBOVAC2 produces high quality results, adheres to all contractual expectations and communicates efficiently to all stakeholders.

 

 

NEWS

  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Cookies settings

×

Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Interactive Content

This site uses third-party components, such as ReCAPTCHA, Google Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Other cookies

Our wepage uses cookies to manage user sessions